Bristol Current Deferred Revenue from 2010 to 2024

BMY Stock  USD 58.78  0.09  0.15%   
Bristol Myers Current Deferred Revenue yearly trend continues to be fairly stable with very little volatility. Current Deferred Revenue is likely to outpace its year average in 2024. Current Deferred Revenue is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. View All Fundamentals
 
Current Deferred Revenue  
First Reported
2001-03-31
Previous Quarter
3.9 B
Current Value
2.7 B
Quarterly Volatility
1.2 B
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Bristol Myers financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bristol Myers' main balance sheet or income statement drivers, such as Depreciation And Amortization of 10.3 B, Interest Expense of 1.2 B or Selling General Administrative of 3.6 B, as well as many indicators such as Price To Sales Ratio of 2.98, Dividend Yield of 0.0374 or PTB Ratio of 6.92. Bristol financial statements analysis is a perfect complement when working with Bristol Myers Valuation or Volatility modules.
  
Check out the analysis of Bristol Myers Correlation against competitors.

Latest Bristol Myers' Current Deferred Revenue Growth Pattern

Below is the plot of the Current Deferred Revenue of Bristol Myers Squibb over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Bristol Myers' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bristol Myers' overall financial position and show how it may be relating to other accounts over time.
Current Deferred Revenue10 Years Trend
Slightly volatile
   Current Deferred Revenue   
       Timeline  

Bristol Current Deferred Revenue Regression Statistics

Arithmetic Mean2,642,800,000
Geometric Mean1,323,600,850
Coefficient Of Variation107.82
Mean Deviation2,311,493,333
Median1,167,000,000
Standard Deviation2,849,461,734
Sample Variance8119432.2T
Range8.7B
R-Value0.61
Mean Square Error5509988.5T
R-Squared0.37
Significance0.02
Slope387,492,857
Total Sum of Squares113672050.4T

Bristol Current Deferred Revenue History

20248.8 B
20238.4 B
20221.3 B
20213.7 B
20203.6 B
20194.5 B
2018172 M

About Bristol Myers Financial Statements

Bristol Myers investors use historical fundamental indicators, such as Bristol Myers' Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Bristol Myers. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue8.4 B8.8 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Bristol Stock Analysis

When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.